ABSTRACT
In principle, single-arm phase II trials evaluate whether a new regimen is sufficiently promising to warrant a comparison with the current standard of treatment. An agent is considered sufficiently promising based on the proportion of patients who respond, that is, experience some objective measure of disease improvement. The toxicity or adverse event profile of the new regimen, usually defined in terms of the proportion of patients experiencing severe adverse events, has been established in a previous phase I trial.
